US 12,171,978 B2
Medical container for accommodating protein solution formulation
Hideaki Kiminami, Kanagawa (JP); Koji Nakamura, Tokyo (JP); Yoshihiko Abe, Kanagawa (JP); Shigeru Suzuki, Kanagawa (JP); and Shigeru Tamatsukuri, Tokyo (JP)
Assigned to TERUMO KABUSHIKI KAISHA, Tokyo (JP)
Filed by TERUMO KABUSHIKI KAISHA, Tokyo (JP)
Filed on Mar. 27, 2017, as Appl. No. 15/470,828.
Application 15/470,828 is a continuation of application No. PCT/JP2015/072633, filed on Aug. 10, 2015.
Claims priority of application No. 2014-203616 (JP), filed on Oct. 2, 2014.
Prior Publication US 2017/0197024 A1, Jul. 13, 2017
Int. Cl. A61K 38/16 (2006.01); A61J 1/00 (2023.01); A61J 1/05 (2006.01); A61J 1/10 (2006.01); A61J 1/14 (2023.01); A61K 9/08 (2006.01); A61K 38/00 (2006.01); A61K 38/18 (2006.01); A61K 39/395 (2006.01); A61L 2/07 (2006.01); A61M 5/00 (2006.01); A61M 5/31 (2006.01); B65D 75/32 (2006.01)
CPC A61M 5/002 (2013.01) [A61J 1/00 (2013.01); A61J 1/05 (2013.01); A61J 1/10 (2013.01); A61J 1/14 (2013.01); A61K 9/08 (2013.01); A61K 38/00 (2013.01); A61K 38/1816 (2013.01); A61K 39/395 (2013.01); A61L 2/07 (2013.01); B65D 75/326 (2013.01); A61L 2202/23 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A product comprising:
a sterilized medical container that suppresses oxidization of amino acid residues, wherein the medical container consists essentially of a cycloolefin polymer and was sterilized with high-pressure steam; and
a stable protein solution accommodated in the medical container, wherein the protein solution comprises a protein selected from the group consisting of erythropoietin, a granulocyte colony-stimulating factor, thrombopoietin, a tissue plasminogen activator, a stem cell growth factor, an interferon, and an interleukin, and wherein 5% or less of methionine residues in the protein are oxidized immediately after accommodation in the medical container and for at least 4 weeks thereafter.